Natixis Advisors LLC Sells 9,058 Shares of Repligen Corporation $RGEN

Natixis Advisors LLC lowered its position in shares of Repligen Corporation (NASDAQ:RGEN) by 23.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,271 shares of the biotechnology company’s stock after selling 9,058 shares during the quarter. Natixis Advisors LLC’s holdings in Repligen were worth $4,796,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Iron Triangle Partners LP bought a new stake in shares of Repligen during the third quarter worth $36,091,000. Hudson Bay Capital Management LP bought a new stake in shares of Repligen during the third quarter worth $2,807,000. Cinctive Capital Management LP bought a new stake in shares of Repligen during the third quarter worth $3,398,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Repligen during the fourth quarter worth $199,176,000. Finally, Schroder Investment Management Group raised its position in shares of Repligen by 123.2% during the third quarter. Schroder Investment Management Group now owns 460,609 shares of the biotechnology company’s stock worth $61,570,000 after acquiring an additional 254,212 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 2.5%

NASDAQ:RGEN opened at $125.33 on Tuesday. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.07 billion, a price-to-earnings ratio of 139.26, a PEG ratio of 2.36 and a beta of 1.09. The stock has a 50-day moving average price of $118.88 and a two-hundred day moving average price of $138.50.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the previous year, the firm earned $0.39 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Canaccord Genuity Group dropped their target price on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. JPMorgan Chase & Co. dropped their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Wolfe Research assumed coverage on Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Finally, Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.